BridgeBio Pharma, Inc. (BBIO) Free cash flow 2017–2025
BridgeBio Pharma, Inc. (BBIO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$447.0MFY2025 · since FY2017: -$41.0M → -$447.0M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$447.0M | +14.3% |
| FY2024 | -$521.7M | +1.4% |
| FY2023 | -$529.0M | -24.7% |
| FY2022 | -$424.3M | +17.0% |
| FY2021 | -$511.2M | -25.5% |
| FY2020 | -$407.2M | -58.9% |
| FY2019 | -$256.2M | -84.6% |
| FY2018 | -$138.8M | -239.0% |
| FY2017 | -$41.0M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice